79 related articles for article (PubMed ID: 7705697)
21. [Mutation of breast cancer susceptibility gene in ovarian cancer and its clinical significance].
Shi H; You Z; Guo Y
Zhonghua Fu Chan Ke Za Zhi; 1998 Nov; 33(11):676-8. PubMed ID: 10806719
[TBL] [Abstract][Full Text] [Related]
22. [Recommendations for the management of women with an increased genetic risk of gynaecological cancer].
Verheijen RH; Boonstra H; Menko FH; de Graaff J; Vasen HF; Kenter GG
Ned Tijdschr Geneeskd; 2002 Dec; 146(50):2414-8. PubMed ID: 12518519
[TBL] [Abstract][Full Text] [Related]
23. [In cases of familial ovarian cancer, always consider the risk of breast cancer].
Kets CM; Niermeijer MF; Massuger LF; Hoogerbrugge N
Ned Tijdschr Geneeskd; 2004 Aug; 148(35):1709-11. PubMed ID: 15468897
[TBL] [Abstract][Full Text] [Related]
24. [Prophylactic mastectomy in women at high risk for breast and ovarian cancer: qualitative analysis of the decision making process and long-term satisfaction of two women carrying a BRCA1-mutation].
Vodermaier A; Bauerfeind I; Untch M; Nestle-Krämling C
Psychother Psychosom Med Psychol; 2006; 56(9-10):351-61. PubMed ID: 16804803
[TBL] [Abstract][Full Text] [Related]
25. [INSERM-FNCLCC collective expertise. Recommendations for medical management of women with genetic risk of developing breast and/or ovarian cancer].
Eisinger F; Alby N; Bremond A; Dauplat J; Espié M; Janiaud P; Kuttenn F; Lebrun JP; Lefranc JP; Pierret J; Sobol H; Stoppa-Lyonnet D; Thouvenin D; Tristant H; Feingold J
Ann Genet; 1999; 42(1):51-64. PubMed ID: 10214508
[TBL] [Abstract][Full Text] [Related]
26. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group.
Metcalfe KA; Lubinski J; Ghadirian P; Lynch H; Kim-Sing C; Friedman E; Foulkes WD; Domchek S; Ainsworth P; Isaacs C; Tung N; Gronwald J; Cummings S; Wagner T; Manoukian S; Møller P; Weitzel J; Sun P; Narod SA;
J Clin Oncol; 2008 Mar; 26(7):1093-7. PubMed ID: 18195327
[TBL] [Abstract][Full Text] [Related]
27. [DNA-analysis in hereditary cancer: the importance of a reliable family history].
Kapma S; Leschot NJ; Aalfs CM
Ned Tijdschr Geneeskd; 2005 Jan; 149(2):57-60. PubMed ID: 15688834
[TBL] [Abstract][Full Text] [Related]
28. Prophylactic oophorectomy in inherited breast/ovarian cancer families.
Struewing JP; Watson P; Easton DF; Ponder BA; Lynch HT; Tucker MA
J Natl Cancer Inst Monogr; 1995; (17):33-5. PubMed ID: 8573450
[TBL] [Abstract][Full Text] [Related]
29. Is family history related to preventive health behaviors and medical management in breast cancer patients?
Madlensky L; Flatt SW; Bardwell WA; Rock CL; Pierce JP;
Breast Cancer Res Treat; 2005 Mar; 90(1):47-54. PubMed ID: 15770526
[TBL] [Abstract][Full Text] [Related]
30. Hereditary ovarian cancer: a dilemma in prognosis.
Klein B; Lurie H; Stein M; Kuten A; Steinherz R
Isr J Med Sci; 1992 Jan; 28(1):16-9. PubMed ID: 1733892
[TBL] [Abstract][Full Text] [Related]
31. The role of prophylactic oophorectomy in cancer prevention.
Averette HE; Nguyen HN
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S38-41. PubMed ID: 7835808
[TBL] [Abstract][Full Text] [Related]
32. [Hereditary breast cancer: treatment and prevention].
Ejlertsen B; Gerdes AM
Ugeskr Laeger; 2007 Sep; 169(36):2972-5. PubMed ID: 17953871
[TBL] [Abstract][Full Text] [Related]
33. What would you do? Specialists' perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination.
Matloff ET; Shappell H; Brierley K; Bernhardt BA; McKinnon W; Peshkin BN
J Clin Oncol; 2000 Jun; 18(12):2484-92. PubMed ID: 10856109
[TBL] [Abstract][Full Text] [Related]
34. Current national health insurance coverage policies for breast and ovarian cancer prophylactic surgery.
Kuerer HM; Hwang ES; Anthony JP; Dudley RA; Crawford B; Aubry WM; Esserman LJ
Ann Surg Oncol; 2000 Jun; 7(5):325-32. PubMed ID: 10864338
[TBL] [Abstract][Full Text] [Related]
35. Diagnosing the correct ovarian cancer syndrome.
Trimble EL; Karlan BY; Lagasse LD; Hoskins WJ
Obstet Gynecol; 1991 Dec; 78(6):1023-6. PubMed ID: 1945201
[TBL] [Abstract][Full Text] [Related]
36. Hereditary breast and ovarian cancer: high-risk management.
Craft M
Oncology (Williston Park); 2007 Oct; 21(11 Suppl Nurse Ed):19-21. PubMed ID: 18154204
[No Abstract] [Full Text] [Related]
37. The loss of a mother and dealing with genetic cancer risk: women who have undergone prophylactic removal of the ovaries.
Mæland MK; Eriksen EO; Synnes O
Eur J Oncol Nurs; 2014 Oct; 18(5):521-6. PubMed ID: 24880189
[TBL] [Abstract][Full Text] [Related]
38. Medical expenditures of terminal cancer patients during the last year of life.
Long SH; Gibbs JO; Crozier JP; Cooper DI; Newman JF; Larsen AM
Inquiry; 1984; 21(4):315-27. PubMed ID: 6240463
[TBL] [Abstract][Full Text] [Related]
39. Insurance policies for prophylactic mastectomy: to cover or not to cover?
Piver MS
Ann Surg Oncol; 2000 Oct; 7(9):714. PubMed ID: 11034252
[No Abstract] [Full Text] [Related]
40. Death of insured no bar to tort cause of action for bad faith denial of coverage of medical treatment. Weatherly v. Blue Cross Blue Shield Insurance Company.
Allred KJ
J Health Hosp Law; 1995; 28(1):38-43. PubMed ID: 10184276
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
